Instrument Inactif

Communiqués Anacor Pharmaceuticals Inc

Actions

US0324201013

Recherche biotechnologique et médicale

Cours en clôture Nasdaq
- ^USD	-

16/05/16	Anacor Pharmaceuticals : Pfizer rachète Anacor Pharma pour 5,2 milliards de dollars	RE
16/05/16	Pfizer rachète Anacor Pharma pour $5,2 milliards	RE

Communiqués

21/05/16	Brodsky & Smith, LLC Announces Investigation of The Board of Directors of Anacor Pharmaceuticals, Inc.	BU
20/05/16	Levi & Korsinsky, LLP Announces Investigation Into Whether the Sale of Anacor Pharmaceuticals, Inc. to Pfizer Inc. for $99.25 Per Share is Fair to Shareholders	BU
19/05/16	Levi & Korsinsky, LLP Announces Investigation Regarding the Fairness of the Sale of Anacor Pharmaceuticals, Inc. to Pfizer Inc. for $99.25 Per Share	BU
18/05/16	Ryan & Maniskas, LLP : Announces Investigation of Anacor Pharmaceuticals, Inc.	PR
17/05/16	Brower Piven Commences an Investigation into the Proposed Sale of Anacor Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm for Additional Information	BU
16/05/16	Brower Piven Commences an Investigation into the Proposed Sale of Anacor Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm for Additional Information	BU
16/05/16	ANACOR PHARMACEUTICALS, INC. Rigrodsky & Long, P.A. Announces Investigation Of Buyout	BU
10/05/16	Anacor Pharmaceuticals : Reports First Quarter 2016 Financial Results	BU
09/05/16	Anacor Pharmaceuticals : to Report First Quarter 2016 Financial Results on May 10, 2016	PU
04/05/16	Anacor Pharmaceuticals : to Report First Quarter 2016 Financial Results on May 10, 2016	BU
02/05/16	Anacor Pharmaceuticals : to Present at the Deutsche Bank 41st Annual Healthcare Conference	BU
01/04/16	Anacor Pharmaceuticals : Announces Pricing of Offering of $250 Million of 2.00% Convertible Senior Notes Due 2023	BU
30/03/16	Anacor Pharmaceuticals : Announces Proposed Offering of $250 Million of Convertible Senior Notes Due 2023	BU
22/03/16	Anacor Pharmaceuticals : Announces FDA Acceptance of NDA for Crisaborole Topical Ointment, 2% for the Treatment of Mild-to-Moderate Atopic Dermatitis	BU
03/03/16	Anacor Pharmaceuticals : to Present at the Cowen and Company 36th Annual Health Care Conference	BU
29/02/16	Anacor Pharmaceuticals : Reports 2015 Fourth Quarter and Year-End Financial Results	BU
23/02/16	Anacor Pharmaceuticals : Announces Late-Breaking Oral Presentation of Crisaborole Topical Ointment, 2% Phase 3 Pivotal Data at the 74th Annual Meeting of the American Academy of Dermatology	BU
22/02/16	Anacor Pharmaceuticals : Announces 2015 Fourth Quarter and Year-End Financial Results Conference Call and Webcast	BU
08/01/16	Anacor Pharmaceuticals : to Present Data From Long-Term Safety Study of Crisaborole Topical Ointment, 2% in Patients With Mild-to-Moderate Atopic Dermatitis at Upcoming Medical Conference	BU
07/01/16	Anacor Pharmaceuticals : Submits New Drug Application to the FDA for Crisaborole Topical Ointment, 2% for the Treatment of Mild-to-Moderate Atopic Dermatitis	BU
12/11/15	Anacor Pharmaceuticals : to Present at the Jefferies Autumn 2015 Global Healthcare Conference	BU
03/11/15	Anacor Pharmaceuticals : Reports Third Quarter 2015 Financial Results	BU
29/10/15	Anacor Pharmaceuticals : Announces Top-Line Results From Long-Term Safety Study of Crisaborole Topical Ointment, 2% in Patients With Mild-to-Moderate Atopic Dermatitis	BU
28/10/15	Anacor Pharmaceuticals : to Report Third Quarter 2015 Financial Results on November 3, 2015	BU
29/09/15	Anacor Pharmaceuticals : Announces Presentations of Crisaborole Topical Ointment, 2% Phase 3 Pivotal Data at Two Upcoming Medical Conferences	BU